Navigation Links
454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
Date:9/27/2007

profiling and gene expression applications," explained Michael Egholm, Ph.D., Vice President of Research and Development at 454 Life Sciences. "These and other applications enabled by 454 Sequencing are opening the door on social genomics. We are going to learn about how social behavior is coded in the genome and how it has evolved, which could have a lot of relevance to understanding human behavior."

454 Life Sciences develops and commercializes the innovative Genome Sequencer(TM) system for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of whole genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of 454 Sequencing(TM) are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired reads. 454 Sequencing technology has enabled many peer-reviewed studies in diverse research fields such as: cancer research, infectious diseases research, drug discovery, marine biology, anthropology, paleontology, and many more.

For additional information, please visit http://www.454.com.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Dia
'/>"/>

SOURCE 454 Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
7. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
8. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
9. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... discover technological and commercial prospects What does ... market? Visiongain,s brand new report shows you ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2
... DUBLIN, October 30 Shire plc (LSE: SHP, NASDAQ:,SHPGY) the global specialty biopharmaceutical company, announces results for,the three months to September ... ... Q3 2009(1), Product sales ... million -15%, Product sales from core products(2) ...
... TAIPEI, Taiwan, Oct. 30 ... in Beijing: from bench to bedside and community, ... This solution entails a series of,innovative professional ... diagnosis, and treatment follow-up. Microlife successfully,developed several ...
Cached Medicine Technology:Shire Continues to Deliver Excellent Growth From Core Products 2Shire Continues to Deliver Excellent Growth From Core Products 3Shire Continues to Deliver Excellent Growth From Core Products 4Shire Continues to Deliver Excellent Growth From Core Products 5Shire Continues to Deliver Excellent Growth From Core Products 6Shire Continues to Deliver Excellent Growth From Core Products 7Shire Continues to Deliver Excellent Growth From Core Products 8Shire Continues to Deliver Excellent Growth From Core Products 9Shire Continues to Deliver Excellent Growth From Core Products 10Shire Continues to Deliver Excellent Growth From Core Products 11Shire Continues to Deliver Excellent Growth From Core Products 12Shire Continues to Deliver Excellent Growth From Core Products 13Shire Continues to Deliver Excellent Growth From Core Products 14Shire Continues to Deliver Excellent Growth From Core Products 15Shire Continues to Deliver Excellent Growth From Core Products 16Shire Continues to Deliver Excellent Growth From Core Products 17Shire Continues to Deliver Excellent Growth From Core Products 18Shire Continues to Deliver Excellent Growth From Core Products 19Shire Continues to Deliver Excellent Growth From Core Products 20Shire Continues to Deliver Excellent Growth From Core Products 21Shire Continues to Deliver Excellent Growth From Core Products 22Shire Continues to Deliver Excellent Growth From Core Products 23Shire Continues to Deliver Excellent Growth From Core Products 24Shire Continues to Deliver Excellent Growth From Core Products 25Shire Continues to Deliver Excellent Growth From Core Products 26Shire Continues to Deliver Excellent Growth From Core Products 27Shire Continues to Deliver Excellent Growth From Core Products 28Shire Continues to Deliver Excellent Growth From Core Products 29Shire Continues to Deliver Excellent Growth From Core Products 30Shire Continues to Deliver Excellent Growth From Core Products 31Shire Continues to Deliver Excellent Growth From Core Products 32Shire Continues to Deliver Excellent Growth From Core Products 33Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 2Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 3
(Date:8/28/2014)... 2014 Millennium Treatment Group recently announced a ... large, and Millennium Treatment Group is working to close it, ... need. , According to the National Survey on Drug ... Americans could have benefited from treatment for drug and/or substance ... This means that there is a large treatment gap in ...
(Date:8/28/2014)... August 28, 2014 American adults who ... on the Internet will now have a simpler way ... In one click this year, some of the best ... http://quotespros.com/life-insurance.html . , The promoted plans that included ... finder tool represent popular policies. The term, guaranteed and ...
(Date:8/28/2014)... exit strategy from the war, now may be the time ... to veterans, says a Perspective piece in the New ... doing more of the same is to fail to recognize ... structure pose in the longer run," said William Weeks, from ... David Auerbach, from the RAND Corporation, in the August issue ...
(Date:8/28/2014)... MI (PRWEB) August 28, 2014 Biotronic, ... nation’s leading intraoperative neurophysiology monitoring ("IONM") company, today announced ... the position of Chief Executive Officer effective immediately. Mr. ... to President and CFO in 2013 and has been ... , “Bill’s efforts and achievements since joining the ...
(Date:8/28/2014)... Idaho (PRWEB) August 28, 2014 Kirklyn Smith, ... on what may be a new world’s record by walking ... desk.At TrekDesk we are constantly amazed by the thousands of ... but some just seem to stand out more than the ... daily 24 hour step count which tallies a range of ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2
... globalization visionOSAKA, Japan, March 30 ... announced a reorganization of its corporate structure, as ... become a global pharmaceutical company with highly integrated ... to rapid changes in the global operating environment ...
... The American Association of Oral and Maxillofacial ... Oral Health Rehabilitative Enhancement Act of 2009" (H.R. 1430 IH), ... referring their Medicare patients for physical therapy. Introduced on March ... (D-N.J.) and Congressman Eric Cantor (R-Va.), ...
... Introduced by the National Association of Boards ... Internet Pharmacy Practice Sites(TM) (VIPPS)(R) program celebrates 10 ... consumers to confidently access important information regarding the ... the nation. A total of 16 pharmacy sites ...
... Technologies, Inc., a developer of advanced visual prosthetic ... today announced the FDA Ophthalmic Devices Advisory Panel ... the premarket application (PMA) for its implantable telescope ... first medical device to be recommended by the ...
... UCSF research team has developed a technique to ... differences in levels of genetic markers. Standard ... and somewhat subjective, the researchers say, and supplementing ... to help clarify difficult-to-diagnose cases. , In a ...
... shows that people with multiple sclerosis may be at a ... of developing certain types of cancer, such as brain tumors ... 31, 2009, print issue of Neurology , the medical ... Researchers looked at the medical records of 20,000 people with ...
Cached Medicine News:Health News:Takeda to Create Global Centers of Excellence 2Health News:Takeda to Create Global Centers of Excellence 3Health News:Takeda to Create Global Centers of Excellence 4Health News:AAOMS Applauds Legislation Enabling Medicare Patients to Rehabilitate and Recover More Efficiently From Oral and Maxillofacial Injuries 2Health News:VIPPS Celebrates 10th Anniversary, Continues to Guide Consumers to Legitimate Internet Pharmacies 2Health News:VIPPS Celebrates 10th Anniversary, Continues to Guide Consumers to Legitimate Internet Pharmacies 3Health News:FDA Advisory Panel Recommends Approval of VisionCare's Implantable Telescope for End-Stage Macular Degeneration 2Health News:FDA Advisory Panel Recommends Approval of VisionCare's Implantable Telescope for End-Stage Macular Degeneration 3Health News:New strategy developed to diagnose melanoma 2Health News:New strategy developed to diagnose melanoma 3Health News:Multiple sclerosis associated with lower cancer risk 2
37°C incubator for DianaGel cards....
ScanGel® Incubator...
... The Mini-PROTEAN 3 Dodeca cell runs up ... in just 35 minutes. Handcast gels can ... the new Model 485 gradient former and ... variation and improving reproducibility. Alternatively, Ready Gel ...
... Mini-PROTEAN 3 Dodeca cell runs up to ... just 35 minutes. Handcast gels can be ... new Model 485 gradient former and Mini-PROTEAN ... and improving reproducibility. Alternatively, Ready Gel precast ...
Medicine Products: